Analysis of PTRHD1 common and rare variants in European patients with Parkinson's disease

Neurobiol Aging. 2021 Nov:107:178-180. doi: 10.1016/j.neurobiolaging.2021.06.005. Epub 2021 Jun 16.

Abstract

Three studies in Iranian and African families identified three different variants in the peptidyl-tRNA hydrolase domain containing 1 gene (PTRHD1) in patients affected by parkinsonism with intellectual impairment. In the current study, our objective was to investigate whether PTRHD1 variants are associated with Parkinson's disease (PD) risk and age at onset (AAO). To evaluate the association between PTRHD1 and PD risk, we analyzed whole genome sequencing data of 1647 PD cases and 1050 healthy controls, as well as genome-wide imputed genotyping data on 14,671 PD cases and 17,667 controls, all of European ancestry. Furthermore, we examined the association of PTRHD1 with PD risk and AAO using summary statistics data from the most recent PD genome-wide association study meta-analyses. Our results show no association between PTRHD1 and PD risk or AAO. We conclude that PTRHD1 does not play a major role in PD in the European population. Further large-scale studies including subjects with different ancestry and family trios are required.

Keywords: Burden test; Familial parkinsonism; GWAS; PTRHD1; Parkinson's disease; SKATO.

Publication types

  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Africa
  • Age of Onset
  • Carboxylic Ester Hydrolases / genetics*
  • Databases, Genetic
  • Europe
  • Female
  • Genetic Testing
  • Genetic Variation / genetics*
  • Genome-Wide Association Study / methods*
  • Humans
  • Iran
  • Male
  • Negative Results*
  • Parkinson Disease / genetics*
  • Risk
  • White People / genetics

Substances

  • Carboxylic Ester Hydrolases
  • aminoacyl-tRNA hydrolase